FTX Settles 600 Million Robinhood Shares Dispute with Emergent Technologies
| EBS Stock | USD 6.50 0.10 1.56% |
Slightly above 55% of Emergent Biosolutions' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Emergent Biosolutions suggests that some traders are interested. Emergent Biosolutions' investing sentiment can be driven by a variety of factors including economic data, Emergent Biosolutions' earnings reports, geopolitical events, and overall market trends.
FTX reaches a 14 million settlement with Emergent Technologies to resolve dispute over 600 million in Robinhood shares
Read at blockonomi.com
 |
Emergent Biosolutions Fundamental Analysis
We analyze Emergent Biosolutions' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Emergent Biosolutions is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Emergent Biosolutions Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Emergent Biosolutions stock to make a market-neutral strategy. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics with similar companies.
Peers
Emergent Biosolutions Related Equities
| CPIX | Cumberland Pharmaceuticals | 15.55 | ||||
| LFCR | Lifecore Biomedical | 2.71 | ||||
| ZTS | Zoetis | 2.04 | ||||
| DRRX | Durect | 1.60 | ||||
| ALKS | Alkermes Plc | 0.70 | ||||
| NBIX | Neurocrine Biosciences | 0.64 | ||||
| PBH | Prestige Brand | 0.70 | ||||
| BHC | Bausch Health | 1.31 | ||||
| COLL | Collegium Pharmaceutical | 1.76 | ||||
| AKAN | Akanda Corp | 3.97 |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.